GDM Risk Assessment (NICE)
Tick applicable NICE risk factors. Any factor = offer OGTT at 24–28 weeks.
Gestational diabetes mellitus (GDM) is defined as glucose intolerance first recognised or diagnosed in pregnancy. It represents a state of relative insulin resistance superimposed on the normal physiological insulin resistance of pregnancy, driven by placental hormones including human placental lactogen, progesterone, and cortisol. GDM affects approximately 5-15% of pregnancies globally, with rates rising in parallel with increasing obesity prevalence and older maternal age at first pregnancy. It is associated with significant risks for both mother and baby: maternal risks include pre-eclampsia, caesarean delivery, and a 7-fold increased lifetime risk of type 2 diabetes; fetal and neonatal risks include macrosomia, birth trauma (shoulder dystocia), polyhydramnios, neonatal hypoglycaemia, respiratory distress syndrome, stillbirth in severe uncontrolled cases, and long-term offspring obesity and metabolic syndrome. NICE identifies specific risk factors that indicate the need for screening with the oral glucose tolerance test (OGTT): BMI ≥30 kg/m², previous GDM, macrosomic baby in a prior pregnancy (birth weight >4.5 kg), first-degree family history of diabetes, and high-risk ethnicity (South Asian, Black African, Middle Eastern, and East Asian). The diagnostic OGTT involves a 75g anhydrous glucose load after an overnight fast; GDM is diagnosed if fasting plasma glucose is ≥5.6 mmol/L or the 2-hour value is ≥7.8 mmol/L. GDM is managed through dietary modification, blood glucose monitoring, and insulin therapy when glycaemic targets are not met with lifestyle measures alone.
GDM Diagnosis (OGTT 75g): Fasting glucose ≥5.6 mmol/L (100 mg/dL) OR 2-hour glucose ≥7.8 mmol/L (140 mg/dL); NICE Risk Factors for OGTT screening at 24-28 weeks: BMI ≥30, previous GDM, previous macrosomia >4.5 kg, first-degree family DM, South Asian/Black African/Middle Eastern/East Asian ethnicity, or PCOS
- 1Assess GDM risk factors at the booking appointment (usually 8-12 weeks): BMI, ethnicity, personal history of GDM in previous pregnancies, family history (first-degree relative with type 2 diabetes or GDM), previous macrosomic baby, and history of PCOS.
- 2If any risk factor is present, offer OGTT at 24-28 weeks of gestation. In women with previous GDM, offer OGTT as early as 16-18 weeks; if normal, repeat at 24-28 weeks.
- 3Prepare for OGTT: the patient must fast from midnight (at least 8 hours), take nothing except water, and avoid smoking and strenuous exercise. Fasting plasma glucose is drawn first.
- 4Administer 75g of anhydrous glucose dissolved in 250-300 mL of water over 5 minutes. The patient remains rested and fasting. Plasma glucose is measured at exactly 2 hours after the glucose load.
- 5Interpret results: normal = fasting <5.6 mmol/L AND 2-hour <7.8 mmol/L; GDM = fasting ≥5.6 mmol/L OR 2-hour ≥7.8 mmol/L (NICE criteria). WHO criteria for GDM: fasting ≥5.1 mmol/L or 2-hour ≥8.5 mmol/L (note: WHO criteria differ from NICE).
- 6If GDM is diagnosed, refer to a multidisciplinary diabetes-in-pregnancy team. Initiate dietary counselling (low glycaemic index carbohydrates, distributed across 3 meals and 3 snacks) and begin blood glucose monitoring (fasting, 1-hour post-prandial targets).
- 7If blood glucose targets are not met within 1-2 weeks of dietary modification, initiate pharmacological therapy: metformin first-line if tolerated; insulin added if metformin insufficient or contraindicated. Monitor with serial ultrasound growth scans (from 28 weeks) and aim for delivery at 38-40 weeks in diet-controlled GDM, 37-38 weeks in insulin-controlled GDM.
Add family history DM as third risk factor; early booking advice on diet and weight gain targets
This woman has multiple GDM risk factors. Early dietary advice to prevent excessive gestational weight gain may reduce GDM risk. OGTT at 24-28 weeks is mandatory; if negative, lifestyle advice continues.
Refer to diabetes in pregnancy team; dietary modification; BG monitoring 4x daily; growth USS from 28 weeks
Under NICE criteria, either threshold alone is diagnostic. A fasting glucose of 5.8 mmol/L indicates impaired fasting glucose in pregnancy and carries the same fetal risk as combined threshold elevation.
Rapid-acting insulin (e.g., NovoRapid or Humalog) before main meals; titrate from 4 units; NICE target: 1-hour PP <7.8 mmol/L
Post-prandial glucose consistently above 7.8 mmol/L at 1 hour despite dietary optimisation requires insulin to prevent macrosomia, polyhydramnios, and related complications. Insulin dose is titrated upward every 2-3 days until target is achieved.
Recurrence risk is approximately 50%; early testing prevents delayed diagnosis in high-risk group
Recurrence of GDM is common (approximately 30-50% in subsequent pregnancies). Early OGTT at 16 weeks enables early dietary intervention if positive. A normal early OGTT does not eliminate the need for repeat testing at 24-28 weeks.
Mortgage lenders and loan officers use Gestational Diabetes Risk to structure repayment schedules, compare fixed versus adjustable rate options, and calculate total borrowing costs for residential and commercial real estate transactions across different term lengths.
Personal finance advisors apply Gestational Diabetes Risk when counseling clients on debt reduction strategies, comparing the mathematical benefit of accelerated payments against alternative investment returns to determine the optimal allocation of surplus cash flow.
Credit unions and community banks rely on Gestational Diabetes Risk to generate accurate Truth in Lending disclosures, ensure regulatory compliance with TILA and RESPA requirements, and provide borrowers with standardized cost comparisons across competing loan products.
Corporate treasury departments use Gestational Diabetes Risk to model the cost of revolving credit facilities, term loans, and commercial paper programs, optimizing the company's capital structure and minimizing weighted average cost of debt financing.
Zero or negative interest rate
In practice, this edge case requires careful consideration because standard assumptions may not hold. When encountering this scenario in gestational diabetes risk calculations, practitioners should verify boundary conditions, check for division-by-zero risks, and consider whether the model's assumptions remain valid under these extreme conditions.
Balloon payment at maturity
In practice, this edge case requires careful consideration because standard assumptions may not hold. When encountering this scenario in gestational diabetes risk calculations, practitioners should verify boundary conditions, check for division-by-zero risks, and consider whether the model's assumptions remain valid under these extreme conditions.
Variable rate mid-term adjustment
In practice, this edge case requires careful consideration because standard assumptions may not hold. When encountering this scenario in gestational diabetes risk calculations, practitioners should verify boundary conditions, check for division-by-zero risks, and consider whether the model's assumptions remain valid under these extreme conditions.
Steroid-Induced Hyperglycaemia
Corticosteroids given for fetal lung maturity in threatened preterm delivery can cause significant transient hyperglycaemia, particularly in women with GDM risk factors. Blood glucose should be monitored 4-6 times daily for 24-48 hours after steroid administration. Sliding-scale insulin may be required. Pre-existing GDM may decompensate and require insulin escalation during steroid therapy.
| Guideline | Fasting Threshold | 1-hour Threshold | 2-hour Threshold |
|---|---|---|---|
| NICE (UK) 2015 | ≥5.6 mmol/L | Not routinely measured | ≥7.8 mmol/L |
| WHO 2013 / IADPSG | ≥5.1 mmol/L | ≥10.0 mmol/L | ≥8.5 mmol/L |
| ACOG (USA) | ≥5.3 mmol/L (95mg/dL) | ≥10.0 mmol/L (180mg/dL) | ≥8.6 mmol/L (155mg/dL) |
| ADA (USA) | ≥5.1 mmol/L | ≥10.0 mmol/L | ≥8.5 mmol/L |
What are the diagnostic criteria for GDM?
NICE (UK) criteria: fasting plasma glucose ≥5.6 mmol/L or 2-hour OGTT glucose ≥7.8 mmol/L. WHO (2013) criteria: fasting ≥5.1 mmol/L, 1-hour ≥10.0 mmol/L, or 2-hour ≥8.5 mmol/L. IADPSG criteria (used in the USA, Europe) match WHO 2013. The different thresholds reflect different policy decisions about treatment benefit versus burden; local guidelines should be followed.
Can GDM be prevented?
Risk can be reduced but not fully prevented. Pre-pregnancy weight management, physical activity, and a low glycaemic index diet reduce GDM risk by 20-30% in high-risk women. Metformin in pre-pregnancy period is being evaluated in research settings. Once pregnant, avoiding excess gestational weight gain and following dietary advice from booking reduces severity and improves outcomes even if GDM develops.
Does GDM resolve after delivery?
GDM resolves in most women immediately after delivery when placental hormones are cleared. However, women with GDM have a 7-fold elevated lifetime risk of type 2 diabetes (approximately 50% develop it within 10 years). A postnatal OGTT at 6-13 weeks is recommended to exclude persistent diabetes; if normal, annual fasting glucose checks are advised.
How is GDM managed with diet?
Dietary management focuses on: distributing carbohydrate intake across 3 meals and 2-3 snacks to avoid post-prandial spikes; selecting low glycaemic index carbohydrates (oats, pulses, wholegrain bread); limiting refined sugars and high-GI foods; and ensuring adequate protein and healthy fat intake. Carbohydrate intake should be approximately 40-45% of total energy, reduced from the usual 50-55%.
What are the blood glucose targets in GDM?
NICE targets: fasting glucose ≤5.3 mmol/L; 1 hour post-prandial ≤7.8 mmol/L. Some guidelines use 2-hour post-prandial target ≤6.4 mmol/L. If fasting glucose is above 7.0 mmol/L or 2-hour above 9.0 mmol/L, insulin therapy is initiated promptly without a dietary modification trial. Target HbA1c in GDM managed with insulin is ≤48 mmol/mol (6.5%).
Is metformin safe in pregnancy?
Metformin crosses the placenta. Long-term follow-up studies have not shown adverse effects on child development. NICE permits metformin as first-line pharmacological therapy for GDM when dietary measures fail, particularly for post-prandial hyperglycaemia. However, insulin is more effective at achieving tight glycaemic control and is preferred when glucose is substantially elevated or when fasting glucose is the primary issue.
What fetal complications does uncontrolled GDM cause?
In the context of Gestational Diabetes Risk, this depends on the specific inputs, assumptions, and goals of the user. The underlying formula provides a deterministic relationship between inputs and output, but real-world application requires interpreting the result within the broader context of finance and lending practice. Professionals typically cross-reference calculator output with industry benchmarks, historical data, and regulatory requirements. For the most reliable results, ensure inputs are sourced from verified data, understand which assumptions the formula makes, and consider running multiple scenarios to bracket the range of likely outcomes.
When should delivery be planned in GDM?
NICE recommends: diet-controlled GDM — offer induction or caesarean by 40+6 weeks (same as uncomplicated singleton); insulin-controlled GDM — offer by 38+6 weeks; if complications (macrosomia, hypertension, suboptimal glucose control) — earlier delivery individually assessed. Induction is safe and appropriate to prevent late stillbirth and should be discussed from 38-40 weeks.
Pro Tip
When counselling women with GDM about post-prandial glucose monitoring, emphasise the 1-hour post-prandial check over the 2-hour check — it is more sensitive for detecting macrosomia risk and is the NICE-recommended timepoint. A consistent 1-hour value above 7.8 mmol/L despite optimised diet warrants metformin or insulin even if fasting glucose is within target.
Did you know?
The discovery that maternal hyperglycaemia causes fetal macrosomia was first clearly articulated by the Danish physician Jørgen Pedersen in the 1950s. He proposed the 'Pedersen hypothesis' — that maternal glucose crosses the placenta, stimulates fetal insulin secretion, and drives fetal growth. This mechanistic insight, now more than 70 years old, underpins all modern GDM management strategies and has driven the development of diagnostic criteria specifically designed to prevent macrosomia-related birth complications.
References
- ›NICE Guideline NG3 — Diabetes in pregnancy: management from preconception to the postnatal period. 2015 (updated 2023).
- ›WHO Diagnostic Criteria and Classification of Hyperglycaemia First Detected in Pregnancy. 2013.
- ›HAPO Study Cooperative Research Group. Hyperglycemia and Adverse Pregnancy Outcomes. NEJM 2008.
- ›ADA Standards of Medical Care in Diabetes — Gestational Diabetes. Diabetes Care 2024.